A comprehensive new review published in World Journal of Pediatrics has synthesized decades of research to elucidate the distinct roles of CHD family proteins in heart development. These proteins, which physically remodel DNA to control gene expression, act as stage-specific choreographers during cardiac formation. The study, led by a team from China (DOI: 10.1007/s12519-026-01049-y), systematically evaluates evidence from human genetics, animal models, and stem-cell systems to assign specific cardiac functions to different CHD family members.
The findings reveal a clear division of labor: CHD7 plays a dominant role in early morphogenetic events that build the heart's structure, CHD3 and CHD4 act as 'identity guardians' ensuring correct cell fate during chamber formation, and CHD8 regulates later ventricular growth and functional maturation. Notably, CHD7 is the gene most frequently mutated in CHARGE syndrome, linking it strongly to outflow-tract defects. The review emphasizes that while these proteins appear to act at different stages—early for CHD7, mid for CHD4, and late for CHD8—direct proof of their coordinated action is lacking. To guide future research, the authors propose three testable models: parallel, sequential, and compensatory.
'The data show that we cannot treat these proteins as a single, interchangeable group. They have very distinct, stage-specific jobs,' the authors stated. 'For example, CHD7 is the key player in the early morphogenetic events that build the heart's structure, while CHD4 helps lock in the identity of heart cells as they differentiate. This refined view points us toward which specific gene to look at when studying different types of heart defects, and it opens the door to asking whether these remodelers work together or buffer each other's loss.'
The implications for clinical practice are direct. For genetic screening, the study provides clear priorities: CHD7 for outflow-tract defects, CHD4 for chamber-patterning anomalies, and CHD8 for ventricular dysfunction. This prioritization could improve diagnostic efficiency. Therapeutically, while directly targeting remodelers is risky due to their broad expression, identifying their downstream pathways—such as those regulating cardiomyocyte proliferation or metabolism—may offer safer drug targets. Future studies combining time-resolved multi-omics and combinatorial genetics could uncover how these proteins coordinate across development, potentially paving the way for precise, temporally controlled epigenetic therapies.
The research was supported by multiple Chinese funding agencies, including the National Key Research and Development Program of China and the National Natural Science Foundation of China.
